Oruka Therapeutics, Inc. - Common Stock (NQ:ORKA)

82.11 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Oruka Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >

Oruka Stock Is Now Up Nearly 700%. Here's What a $687,000 Insider Sale Could Mean ↗

June 27, 2026

This biotech innovator in monoclonal antibody therapies reported a notable insider sale amid ongoing clinical-stage developments.

Via The Motley Fool

Topics Regulatory Compliance

Oruka Therapeutics' Head of Finance Sold Over 10,000 Company Shares. What Does That Mean for Investors? ↗

June 24, 2026

This Menlo Park biotech specializing in antibody therapies saw a notable insider sale following a year of rapid gains in its share price.

Via The Motley Fool

Topics Regulatory Compliance

An Oruka Therapeutics (ORKA) Insider Sold 105,000 Shares Worth $6.2 Million ↗

May 31, 2026

This clinical-stage biotech focused on antibody therapies for immunological disorders reported a notable insider sale in its latest filing.

Via The Motley Fool

Topics Regulatory Compliance

MoonLake Stock Climbs After-Hours: Retail Traders Shrug Off Record Plunge, More Wall Street Downgrades ↗

September 29, 2025

Via Stocktwits

Why This Biotech Fund Added $7 Million to an Oncology Stock Up 120% ↗

May 13, 2026

This biotech specializes in small molecule kinase inhibitors for cancer, with lead drug candidates in early-stage clinical trials.

Via The Motley Fool

Topics Regulatory Compliance

Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer Company ↗

May 13, 2026

This clinical-stage biotech develops targeted radiopharmaceutical therapies for cancer using a proprietary miniprotein platform.

Via The Motley Fool

Topics Initial Public Offering Regulatory Compliance

Why This Biotech Fund Increased Its Oruka Therapeutics Stake Amid a Staggering 500% Rally ↗

May 13, 2026

This clinical-stage biotech develops monoclonal antibody therapies targeting psoriasis and other immunology indications.

Via The Motley Fool

Topics Regulatory Compliance

A Tiny Biotech Just Beat AbbVie's $17 Billion Drug. Should Investors Be Worried? ↗

May 11, 2026

It's not the news that AbbVie needed, given the challenging year it is having.

Via The Motley Fool

These stocks are gapping in today's session ↗

April 27, 2026

Via Chartmill

Top movers in Monday's pre-market session ↗

April 27, 2026

Via Chartmill

Oruka Insider Sells $463K in Stock as Shares Skyrocket 650%, but Here's What Matters for Investors ↗

April 21, 2026

This Menlo Park biotech, focused on monoclonal antibody therapies, reported a notable insider sale amid a year of dramatic share gains.

Via The Motley Fool

Topics Regulatory Compliance

Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools ↗

March 18, 2026

Spyre Therapeutics focuses on antibody therapies for inflammatory bowel disease, advancing a pipeline aimed at gastrointestinal health.

Via The Motley Fool

What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down ↗

March 18, 2026

This ophthalmic biopharma firm develops sustained drug delivery therapies for eye diseases, targeting both U.S. and global markets.

Via The Motley Fool

Topics Regulatory Compliance

VR Adviser Adds Over 1 Million Savara Shares ↗

March 15, 2026

This clinical-stage biotech develops inhaled therapies for rare respiratory diseases, with its lead candidate in Phase III trials.

Via The Motley Fool

Topics Regulatory Compliance

Let's take a look at the stocks that are in motion in today's session. ↗

March 13, 2026

Via Chartmill

This Gilead Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

November 13, 2025

Via Benzinga

AutoZone To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Thursday ↗

November 13, 2025

Via Benzinga

Oruka Therapeutics Inc (NASDAQ:ORKA) Reports Q3 2025 Results, Beats EPS Estimates and Provides Clinical Pipeline Updates ↗

November 12, 2025

Oruka Therapeutics reports Q3 2025 results, beating EPS estimates. With a strong $500.9M cash position, the biotech advances its clinical pipeline for ORKA-001 and ORKA-002.

Via Chartmill

The Insider Report: The Bulls Can Thank Tech ↗

November 02, 2025

Via Benzinga

Stock Market Today: Nasdaq, S&P 500 Futures Rise As Government Enters 2nd Week Of Shutdown—Plug, Lithium Americas, UiPath In Focus ↗

October 06, 2025

U.S. stock futures rose on Monday following Friday’s mixed moves. Futures of major benchmark indices were higher.

Via Benzinga

Topics Stocks

Constellation Brands, Aehr Test Systems And 3 Stocks To Watch Heading Into Monday ↗

October 05, 2025

US stock futures up, focus on Constellation Brands, SkyWater Tech, Aehr Test Systems, Oruka Therapeutics and VCI Global earnings.

Via Benzinga

MoonLake Crashes 89% On Mixed Results For Skin Disease Treatment ↗

September 29, 2025

MoonLake Immunotherapeutics stock crashed Monday after the company posted mixed results for its skin disease drug.

Via Investor's Business Daily

Wednesday's session: gap up and gap down stocks ↗

September 17, 2025

Let's delve into the US markets on Wednesday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.

Via Chartmill

Lyft, Oruka Therapeutics, Roivant Sciences, Workday And Other Big Stocks Moving Higher On Wednesday ↗

September 17, 2025

Via Benzinga

Oruka Therapeutics, Up 20%, Is Trying To Take On AbbVie's Biggest Moneymaker ↗

September 17, 2025

Shares skyrocketed after the company said its drug has a half-life of about 100 days.

Via Investor's Business Daily

Discover the top movers in Wednesday's pre-market session. ↗

September 17, 2025

Before the opening bell on Wednesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.

Via Chartmill

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

September 17, 2025

Via Benzinga

Why New Fortress Energy Shares Are Trading Higher By 41%; Here Are 20 Stocks Moving Premarket ↗

September 17, 2025

Via Benzinga

Chewy, Bausch Health Companies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

March 26, 2025

Via Benzinga

Why GameStop Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket ↗

March 26, 2025

Via Benzinga

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.